Bli medlem
Bli medlem

Du är här

2015-04-10

Actelion Pharmaceuticals Ltd: Actelion issues invitation to 2015 Annual General Meeting of Shareholders

Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2015 Annual
General Meeting of Shareholders. Processed and transmitted by NASDAQ OMX
Corporate Solutions. The issuer is solely responsible for the content of this
announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 10 April 2015
-
Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming
Annual General Meeting (AGM) of Shareholders on behalf of the Board of
Directors. The meeting will take place on Friday, 8 May 2015 (10:00hrs CEST)
at the Congress Center, Messe Basel, Switzerland.

At this year's meeting the Board of Directors is proposing an increase in the
dividend payment to CHF 1.30 per share. Also, following the approval of the
Articles of Association at the 2014 AGM, the Board is proposing for the first
time the approval of a maximum compensation for the non-executive members of
the Board of Directors and the maximum compensation amount for the Actelion
Executive Committee.

After 10 and 15 years of service on Actelion's Board of Directors,
respectively, Mr. Carl Feldbaum and Mr. Werner Henrich will be stepping down
at the AGM. All other Board members will stand for re-election.

Jean-Pierre Garnier, Chairman of the Board of Directors, commented:
"Personally, I enjoyed working with both Carl and Werner, who have greatly
supported Actelion during their long service as integral members on
Actelion's Board of Directors. Their individual contributions to the success
of Actelion will be duly celebrated at the AGM."

In addition to the regular agenda items, the Board is proposing the election
of two new Directors: Mrs. Herna Verhagen, Chief Executive Officer of PostNL
N.V., and Mr. David Stout, a pharmaceutical industry professional who has
announced his resignation from the Board of Shire, plc. at the end of April
2015.

Jean-Pierre Garnier, concluded: "As a current CEO of a company with a very
complex business model, Herna understands the challenges of operating in the
current economic and business climate. David brings a broad experience of the
pharmaceutical business having spent his entire professional career in global
pharma. I am confident that both professionals will make a significant
contribution to Actelion, should our shareholders decide to elect them to the
Board."

NOTES TO SHAREHOLDERS

The Annual General Meeting of Shareholders to approve the Business Report of
the year ending 31 December 2014 will be held on 8 May 2015 at 10.00 CEST at
the Congress Center, Messe Basel, Switzerland.

The invitation was published in the Swiss Official Gazette of Commerce
(Schweizerisches Handelsamtsblatt
) on 10 April 2015 and is available, together with the Company's Annual
Report, onwww.actelion.com/agm.

In order to attend and vote at the Annual General Meeting of Shareholders,
Shareholders must have been registered in the Company's shareholder register
by 27 April 2015 at the latest.

###

NOTES TO EDITORS

AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2015

1. Annual Report 2014, Consolidated Accounts 2014, Statutory Accounts 2014
and Compensation Report 2014

1.1. Approval of Annual Report 2014, Consolidated Financial Statements
2014 and Statutory Financial Statements 2014

1.2. Consultative Vote on the Compensation Report 2014

2. Appropriation of Available Earnings and Distribution Against Reserve
from Capital Contribution

3. Discharge of the Board of Directors and of the Executive Management

4. Board Elections

4.1. Re-Election of the Board of Directors

4.2. Election of New Directors

4.3. Election of the Chairperson of the Board of Directors

4.4. Election of the Compensation Committee

5. Approval of Board Compensation and Executive Management Compensation

5.1. Approval of Board Compensation (Non-Executive Directors)

5.2. Approval of Executive Management Compensation 2016 (Maximum
Amount)

6. Election of Independent Proxy

7. Election of the Statutory Auditors

BIOGRAPHIES OF PROPOSED NEW DIRECTORS

Ms. Herna Verhagen

Herna Verhagen (49), a Dutch citizen, became Chief Executive Officer of PostNL
N.V., a mail, parcel and e-commerce corporation, in April 2012.

Prior to this Ms. Verhagen served as member of the Board of Management of
PostNL N.V. and held various executive positions within the Group. Ms.
Verhagen's portfolio includes corporate strategy, public affairs,
communications, corporate responsibility, human resources and internal audit.

Ms. Verhagen holds a MSc in Human Resource Studies and a LLM in Business Law.

Ms. Verhagen also serves in the Supervisory Board of Rexel S.A. and is a
member of the Executive Committee and General Board of the Confederation of
Netherlands Industry and Employers (VNO-NCW).

Mr. David Stout

David Stout (60), a US citizen, was President, Pharmaceutical Operations at
GlaxoSmithKline, where he was responsible for the company's global
pharmaceutical operations from 2003 to 2008.

Prior to this Mr. Stout was President of GlaxoSmithKline's US pharmaceuticals
business and before that SmithKline Beecham's North American pharmaceuticals
business. Before joining SmithKline Beecham, Mr. Stout worked for many years
at Schering-Plough. With over 20 years of senior management experience, Mr.
Stout brings extensive international sales, marketing, operational and supply
chain experience of the pharmaceutical industry.

Mr. Stout holds a BA in Biology. He serves on the Boards of the public
companies Airgas, Inc. and Jabil, Inc. and the non-public company NanoBio
Corporation. He has served on the Board of Shire, Plc. from 2010 until 2015
and will not stand for re-election at their AGM in April.

Actelion Ltd.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides in patients
with cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including the US, Japan, China, Russia and
Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations&Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by
discussions of strategy, plans or intentions. Such statements include
descriptions of the company's investment and research and development
programs and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and anticipated
customer demand for such products and products in the company's existing
portfolio. Such statements reflect the current views of the company with
respect to future events and are subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future
results, performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those described herein as
anticipated, believed, estimated or expected.

Press Release PDF
http://hugin.info/131801/R/1909746/680903.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#1909746

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.